BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/28/2025 10:45:13 AM | Browse: 132 | Download: 646
 |
Received |
|
2024-09-24 23:29 |
|
Peer-Review Started |
|
2024-10-09 01:18 |
|
First Decision by Editorial Office Director |
|
2024-12-20 11:57 |
|
Return for Revision |
|
2024-12-20 11:57 |
|
Revised |
|
2024-12-21 09:06 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-01-14 03:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-01-14 06:39 |
|
Articles in Press |
|
2025-01-14 06:39 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-21 03:55 |
|
Publish the Manuscript Online |
|
2025-02-28 10:45 |
| ISSN |
1948-9358 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abul Bashar Mohammad Kamrul-Hasan, Joseph M Pappachan, Deep Dutta, Lakshmi Nagendra, Mohammad Shafi Kuchay and Nitin Kapoor |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, MD, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Tirzepatide; Drug adherence; Study drug discontinuation; Adverse events; Withdrawal by the study subjects |
| Core Tip |
The reasons for permanent discontinuation of tirzepatide vs controls (placebo, insulin, and glucagon-like peptide-1 receptor agonists [GLP-1RAs]) are not systematically assessed based on data from randomized controlled trials. We studied 17 randomized controlled trials (n = 14645) and found that the risks of study drug discontinuation were greater with higher doses of tirzepatide than with insulin or GLP-1RAs. Tirzepatide, at all doses, had higher risks of adverse event-related discontinuation than insulin. Such risks were only greater with higher doses of tirzepatide than with placebo or GLP-1RAs. Discontinuation risk due to withdrawal by the study subjects was lower with tirzepatide than with placebo or insulin. |
| Publish Date |
2025-02-28 10:45 |
| Citation |
Kamrul-Hasan ABM, Pappachan JM, Dutta D, Nagendra L, Kuchay MS, Kapoor N. Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis. World J Diabetes 2025; 16(4): 101731 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i4/101731.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i4.101731 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
